Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey

Clinical Biochemistry

Volumn 40, Issue 3-4, 2007, Pages 172-176

  Aybek, H ^a   Ercan, F ^a   Aslan, D ^a   Sahiner T ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Alzheimer's disease; Apolipoprotein E4; Oxidative stress; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; GLUTATHIONE; MALONALDEHYDE;

AGED; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION GENETICS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; FEMALE; GENE FREQUENCY; GLUTATHIONE; HUMANS; MALE; MALONDIALDEHYDE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA; TURKEY;

EID: 33846226106     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.09.005     Document Type: Article

References (42)

1. Depboylu C., Lohmuller F., Du Y., Riemenschneider M., Kurz A., Gasser T., et al. Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci. Lett. 400 (2006) 187-190
2. Hamilton G., Samedi F., Knight J., Archer N., Foy C., Walter S., et al. Polymorphisms in the phosphate and tensin homolog gene are not associated with late-onset Alzheimer's disease. Neurosci. Lett. 401 (2006) 77-80
3. Piscopo P., Manfredi A., Malvezzi-Campeggi L., Crestini A., Spadoni O., Cherchi R., et al. Genetic study of Sardinian patients with Alzheimer's disease. Neurosci. Lett. 398 (2006) 124-128
4. Saunders A.M., Trowers M.K., Shimkets R.A., Blakemore S., Crowther D.J., Mansfield T.A., et al. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim. Biophys. Acta 1502 (2000) 85-94
5. Cedazo-Minguez A., and Cowburn R.F. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J. Cell. Mol. Med. 5 (2001) 254-266
6. Spalletta G., Bernardini S., Bellincampi L., Federici G., Trequattrini A., and Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur. J. Neurol. 13 (2006) 176-182
7. Mayeux R., Stern Y., Ottman R., Tatemichi T.K., Tang M.X., Maestre G., et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann. Neurol. 34 (1993) 752-754
8. Mahley R.W., Weisgraber K.H., and Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5644-5651
9. Guidi I., Galimberti D., Lonati S., Novembrino C., Bamonti F., Triticco M., et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 27 (2006) 262-269
10. Ames B.N., Shigenda M.K., and Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7915-7922
11. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative disease. Ann. Neurol. 38 (1995) 357-366
12. Hayn M., Kremser K., Singewald N., Cairns N., Nemethova M., Lubec B., et al. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci. 59 (1996) 537-544
13. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., Van Bell G., Fillenbaum G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989) 1159-1165
14. Güngen C., Ertan T., Eker E., Yaflar R., and Engin F. The Standardized Mini Mental State Examination in Turkish. 9th Congress of The International Psychogeriatric Association, August 15-20, Vancouver, Canada, (1999)
15. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984) 1356-1364
16. Reisberg B., Ferris S.H., de Leon M.J., and Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. Am. J. Psychiatry 139 (1982) 1136-1139
17. Sambrook J., and Russel D. Molecular Cloning: A Laboratory Manual (2001), Cold Spring Harbor Laboratory Pres, NY
18. Hixon J.E., and Vernier D.T. Restriction isotyping oh the human apolipoprotein E by gene amplification and cleavage with Hhal. J. Lipid Res. 31 (1990) 545-548
19. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
20. Moron M.S., Depierre J.W., and Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta 582 (1979) 67-78
21. Nussbaum R.L., and Ellis C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348 (2003) 1356-1364
22. Sorbi S., Forleo P., Tedde A., Cellini E., Ciantelli M., Bagnoli S., et al. Genetic risk factors in familial Alzheimer's disease. Mech. Agei{dotless}ng Dev. 122 (2001) 1951-1960
23. Kanai M., Shizuka M., Urakami K., Matsubara E., Harigaya Y., Okamoto K., et al. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci. Lett. 267 (1999) 65-68
24. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
25. Raygani A.V., Zahrai M., Raygani A.V., Doosti M., Javadi E., Rezaei M., et al. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neuroscience Lett. 375 (2005) 1-6
26. Okuizumi K., Onodera O., Namba Y., et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat. Genet. 11 2 (1995) 207-209
27. Isbir T., Agachan B., Yilmaz H., Aydi{dotless}n M., Kara I., Eker D., et al. Interaction between apolipoprotein-E and angiotensin-converting enzyme genotype in Alzheimer's disease. Am. J. Alzheimer's Dis. Other Dement. 16 (2001) 205-210
28. Sklavounou E., Economou-Petersen E., Karadima G., Panas M., Avramopoulos D., Varsou A., et al. Apolipoprotein E polymorphism in the Greek population. Clin. Genet. 52 (1997) 216-218
29. Mahley R.W., Palo{eth}lu K.H., Atak Z., Dawson-Pepin J., Langlois A.M., Cheung V., et al. Turkish Heart Study: lipids, lipoproteins and apolipoproteins. J. Lipid Res. 36 (1995) 839-859
30. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71 (2000) 621S-629S
31. Miyata M., and Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14 (1996) 55-61
32. Lovell M.A., Ehmann W.D., Butler S.M., and Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 (1995) 1594-1601
33. Kilicoglu B., Eroglu E., Kilicoglu S.S., Kismet K., and Eroglu F. Effect of abdominal trauma on hemorrhagic shock-induced acute lung injury in rats. World J. Gastroenterol. 12 (2006) 3593-3596
34. Baskol G., Demir H., Baskol M., Ki{dotless}ni{dotless}kli{dotless} E., Ates F., Kocer D., et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38 (2005) 951-955
35. Seljeskog E., Hervig T., and Mansoor M.A. A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin. Biochem. 39 (2006) 947-954
36. Balazs L., and Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19 (1994) 1131-1137
37. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. 150 (1998) 40-44
38. Marklund S.L., Adolfsson R., Gottfries C.G., and Winblad B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J. Neurol. Sci. 67 (1985) 319-325
39. Montine K.S., Olson S.J., Amarnath V., Whetsell Jr. W.O., Graham D.G., and Montine T.J. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol. 150 (1997) 437-443
40. Montine K.S., Reich E., Neely M.D., Sidell K.R., Olson S.J., Markesbery W.R., et al. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J. Neuropathol. Exp. Neurol. 57 (1998) 415-425
41. Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S., et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biol. Med. 27 (1999) 544-553
42. Volicer L., Wells J.M., McKee A.C., and Kowall N.W. Enhanced inhibition of free radical-induced deoxyribose breakdown by Alzheimer brain homogenates. Neurosci. Lett. 270 (1999) 169-172